KaloBios announces preliminary phase 1 results of KB004 study KaloBios Pharmaceuticals announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody, which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study. The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.
News For KBIO From The Last 14 Days
Check below for free stories on KBIO the last two weeks.